semaglutide fibrosis (#wegovy/#ozempic) has better results, thus far, in its phase 3 fatty liver trial than its previous phase 2 trial it seems. 72-week data presented at The Liver Meeting 2024: American Association Semaglutide targets MASH molecular pathways

10.1016/j.sajb.2007.03.006 116 NiehlA.LacommeC.ErbanA.KopkaJ.KrmerU.FisahnJ

intramitochondrial GSH is the main defence against oxidative damage to the electron transport chain Immune regulation lymphocyte proliferation and natural killer cell activity depend on adequate intracellular GSH

This includes studies in nausea associated with medication use,10-15 the nausea of pregnancy,16-18 nausea in some disease states,19,20 nausea associated with surgery,21,22 and nausea associated with motion sickness.23 As another common adverse effect of GLP-1 agonist drug use, constipation can be addressed using fiber supplements

This flexibility supports real-world adherence while maintaining safety parameters established in clinical trials